Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | WNT3A | P56704 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.48 |
| ▸ | SKP1 | P63208 | 1/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30564998 | 1.00 | HRH3 (0.57) | HRH3GPR119MAPTLMNAALDH1A1 | |
| SCHEMBL1432797 | 0.88 | AOC3 (0.57) | HRH3GPR119MAPTLMNAALDH1A1 | |
| SCHEMBL24478925 | 0.86 | GPR119 (0.58) | HRH3GPR119MAPTLMNAALDH1A1 | |
| SCHEMBL29723281 | 0.86 | GPR119 (0.58) | HRH3GPR119MAPTLMNAALDH1A1 | |
| SCHEMBL1432556 | 0.85 | AOC3 (0.57) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1432960 | 0.84 | AOC3 (0.57) | HRH3GPR119MAPTLMNAALDH1A1 | |
| SCHEMBL29723056 | 0.84 | GPR119 (0.62) | HRH3GPR119MAPTLMNAALDH1A1 | |
| SCHEMBL28759744 | 0.84 | GPR119 (0.62) | HRH3GPR119MAPTLMNAALDH1A1 | |
| SCHEMBL22411451 | 0.83 | MAPT (0.61) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6363304 | 0.83 | MEN1 (0.65) | GPR119MAPTLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116490506-B | Fused tricyclic compounds, process for their preparation and their use in medicine | 江苏恒瑞医药股份有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-4253387-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-116490506-A | Fused tricyclic compounds, process for their preparation and their use in medicine | 江苏恒瑞医药股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-114621230-B | Nitrogen-containing heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-114621230-A | Nitrogen-containing heterocyclic compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022111636-A1 | FUSED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| EP-1718307-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-04-29 | — | — | EP | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| EP-1718307-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082089-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | ICOS, EDNRA, NFATC1 | HRH3 1062/4885GPR119 740/4885MAPT 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.